Shomron Ben-Horin
#168,612
Most Influential Person Now
Israeli physician
Shomron Ben-Horin's AcademicInfluence.com Rankings
Shomron Ben-Horinphilosophy Degrees
Philosophy
#10076
World Rank
#13776
Historical Rank
Logic
#7014
World Rank
#8618
Historical Rank
Download Badge
Philosophy
Shomron Ben-Horin's Degrees
- Doctorate Medicine Tel Aviv University
Why Is Shomron Ben-Horin Influential?
(Suggest an Edit or Addition)According to Wikipedia, Shomron Ben-Horin is an Israeli physician, a co-founder & Chief Medical Officer of Evinature, and professor of medicine at the Tel-Aviv University. Shomron Ben-Horin was born and raised in Tel Aviv, Israel.
Shomron Ben-Horin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. (2009) (950)
- Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. (2014) (573)
- Review article: loss of response to anti‐TNF treatments in Crohn’s disease (2011) (496)
- European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. (2009) (410)
- Optimizing anti-TNF treatments in inflammatory bowel disease. (2014) (304)
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. (2016) (302)
- Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. (2010) (294)
- Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. (2013) (293)
- Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. (2015) (292)
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab (2013) (286)
- Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. (2015) (277)
- The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful (2010) (216)
- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease (2014) (175)
- Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima (2015) (175)
- Anti‐tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta‐analysis (2012) (165)
- Tailoring anti-TNF therapy in IBD: drug levels and disease activity (2014) (157)
- TNF Activates a NF-κB–Regulated Cellular Program in Human CD45RA– Regulatory T Cells that Modulates Their Suppressive Function (2010) (152)
- Infliximab-Related Infusion Reactions: Systematic Review (2015) (149)
- Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. (2009) (134)
- Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response (2012) (132)
- Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn’s Disease Using Biomarkers, Capsule Endoscopy, and Imaging (2015) (118)
- Deep learning algorithms for automated detection of Crohn's disease ulcers by video capsule endoscopy. (2019) (110)
- Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. (2011) (109)
- Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis (2018) (108)
- Adalimumab level in breast milk of a nursing mother. (2010) (107)
- The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. (2009) (102)
- Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease (2017) (100)
- Deep learning for wireless capsule endoscopy: a systematic review and meta-analysis. (2020) (99)
- Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab (2017) (98)
- Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn's disease: Systematic review and meta-analysis. (2017) (96)
- Association of Vedolizumab Level, Anti‐Drug Antibodies, and &agr;4&bgr;7 Occupancy With Response in Patients With Inflammatory Bowel Diseases (2017) (93)
- Clinical utility of antihuman lambda chain‐based enzyme‐linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti‐infliximab antibodies (2012) (93)
- Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation. (2016) (92)
- The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab (2011) (92)
- Impact of Cannabis Treatment on the Quality of Life, Weight and Clinical Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Prospective Study (2011) (91)
- The Impact of Colon Cleanliness Assessment on Endoscopists' Recommendations for Follow-Up Colonoscopy (2007) (90)
- Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. (2010) (87)
- Large Symptomatic Pericardial Effusion as the Presentation of Unrecognized Cancer: A Study in 173 Consecutive Patients Undergoing Pericardiocentesis (2006) (87)
- Fecal calprotectin for the prediction of small-bowel Crohn’s disease by capsule endoscopy: a systematic review and meta-analysis (2016) (84)
- Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis. (2014) (82)
- Undetectable anti‐TNF drug levels in patients with long‐term remission predict successful drug withdrawal (2015) (81)
- Oral Crohn's disease: is it a separable disease from orofacial granulomatosis? A review. (2012) (79)
- Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience (2017) (76)
- The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions. (2005) (76)
- The role of very late antigen-1 in immune-mediated inflammation. (2004) (74)
- Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis (2016) (73)
- Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. (2016) (72)
- Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: Antibiotics alone or combined antibiotics/immunomodulators? (2011) (71)
- Obesity, Metabolic Syndrome and the Risk of Development of Colonic Diverticulosis (2012) (71)
- The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. (2016) (62)
- Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines (2008) (60)
- The decline of anti‐drug antibody titres after discontinuation of anti‐TNFs: implications for predicting re‐induction outcome in IBD (2012) (60)
- Treatment of experimental colitis by oral tolerance induction: a central role for suppressor lymphocytes (2000) (60)
- Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. (2018) (56)
- Therapeutic drug monitoring in inflammatory bowel disease (2014) (56)
- Diagnostic value of the biochemical composition of pericardial effusions in patients undergoing pericardiocentesis. (2007) (56)
- Early drug and anti‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy (2018) (54)
- Prediction of patency capsule retention in known Crohn's disease patients by using magnetic resonance imaging. (2016) (54)
- The outcome of a second preparation for colonoscopy after preparation failure in the first procedure. (2009) (54)
- Magnetic resonance enterography in Crohn's disease: a guide to common imaging manifestations for the IBD physician. (2013) (53)
- Prospective Observational Evaluation of Time‐Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study (2018) (52)
- Neuroimmunology of the gut: physiology, pathology, and pharmacology. (2008) (51)
- Reprogrammed and transmissible intestinal microbiota confer diminished susceptibility to induced colitis in TMF−/− mice (2014) (50)
- Cholesterol crystal embolization to the digestive system: characterization of a common, yet overlooked presentation of atheroembolism (2003) (49)
- Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing. (2012) (49)
- A murine model for the study of molecular pathogenesis of radiation proctitis. (2010) (49)
- The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. (2006) (48)
- Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. (2019) (48)
- Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα (2021) (45)
- Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta‐analysis (2017) (44)
- The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? (2015) (44)
- Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn’s Disease (2016) (42)
- Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. (2016) (42)
- Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. (2021) (41)
- Development and Validation of a Novel Diagnostic Nomogram to Differentiate Between Intestinal Tuberculosis and Crohn's Disease: A 6-year Prospective Multicenter Study (2019) (41)
- Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. (2019) (41)
- Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. (2018) (41)
- Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5+ B regulatory cells (2016) (40)
- Capsule Endoscopy, Magnetic Resonance Enterography, and Small Bowel Ultrasound for Evaluation of Postoperative Recurrence in Crohn's Disease: Systematic Review and Meta-Analysis. (2017) (40)
- Prior varicella zoster virus exposure in IBD patients treated by anti‐TNFs and other immunomodulators: implications for serological testing and vaccination guidelines (2012) (40)
- Magnetic resonance enterography versus capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn’s disease (2016) (39)
- Expression of the α1β1 integrin, VLA-1, marks a distinct subset of human CD4+ memory T cells (2003) (39)
- Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy (2020) (39)
- Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. (2014) (38)
- Familial clustering of Crohn's disease in Israel: Prevalence and association with disease severity (2009) (38)
- Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease: systematic review and meta-analysis (2018) (37)
- Lidocaine inhibits epithelial chemokine secretion via inhibition of nuclear factor kappa B activation. (2010) (37)
- α1β1 Integrin+ and Regulatory Foxp3+ T Cells Constitute Two Functionally Distinct Human CD4+ T Cell Subsets Oppositely Modulated by TNFα Blockade1 (2007) (36)
- Real-Time Shear Wave Ultrasound Elastography Differentiates Fibrotic from Inflammatory Strictures in Patients with Crohn's Disease. (2018) (36)
- Diffusion-weighted MRI Enables to Accurately Grade Inflammatory Activity in Patients of Ileocolonic Crohn's Disease: Results from an Observational Study (2017) (35)
- Individualized Dynamics in the Gut Microbiota Precede Crohn's Disease Flares. (2019) (35)
- Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. (2019) (34)
- The Lewis score or the capsule endoscopy Crohn’s disease activity index: which one is better for the assessment of small bowel inflammation in established Crohn’s disease? (2018) (34)
- Antiviral therapy in cytomegalovirus-positive ulcerative colitis: a systematic review and meta-analysis. (2014) (34)
- TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User’s Guide: An Update (2020) (32)
- Ulcer severity grading in video-capsule images of Crohn's disease patients: an ordinal neural network solution. (2020) (32)
- Clinical Outcomes of Surgery Versus Endoscopic Balloon Dilation for Stricturing Crohn’s Disease (2015) (32)
- Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases (2017) (31)
- Prediction of disease complication occurrence in Crohn's disease using phenotype and genotype parameters at diagnosis. (2011) (31)
- Optimizing biologic treatment in IBD: objective measures, but when, how and how often? (2015) (30)
- Familial Mediterranean Fever and Cryptogenic Cirrhosis (2007) (29)
- Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies. (2014) (29)
- Loss of Response to Anti-Tumor Necrosis Factors: What Is the Next Step? (2014) (29)
- Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study (2020) (28)
- Severe and Morbid Obesity in Crohn's Disease Patients: Prevalence and Disease Associations (2013) (28)
- Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study (2018) (27)
- Characterizing the circulating, gliadin‐specific CD4+ memory T cells in patients with celiac disease: linkage between memory function, gut homing and Th1 polarization (2006) (27)
- Video Capsule Endoscopy of the Small Bowel for Monitoring of Crohn's Disease (2015) (27)
- Inflammatory Bowel Disease [IBD] and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD. (2018) (26)
- Magnetic resonance enterography in pregnant women with Crohn’s disease: case series and literature review (2014) (26)
- Autonomic Dysfunction Correlates with Clinical and Inflammatory Activity in Patients with Crohn's Disease (2015) (25)
- Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease (2018) (24)
- Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines (2017) (24)
- Severe Gastrointestinal Inflammation in Adult Dermatomyositis: Characterization of a Novel Clinical Association (2006) (24)
- Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus—A Multicenter Retrospective Study (2017) (24)
- Diffusion-weighted imaging in quiescent Crohn's disease: correlation with inflammatory biomarkers and video capsule endoscopy. (2017) (23)
- Magnetic resonance enterography or video capsule endoscopy – what do Crohn’s disease patients prefer? (2016) (23)
- Cytomegalovirus positive ulcerative colitis: A single center experience and literature review. (2013) (23)
- The role of multimodal treatment in Crohn′s disease patients with perianal fistula: a multicentre retrospective cohort study (2018) (23)
- A novel PillCam Crohn’s capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn’s disease (2020) (23)
- Travel-associated health risks for patients with inflammatory bowel disease. (2012) (23)
- Antigenic response to CT‐P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition (2018) (22)
- Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists (2019) (22)
- Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience. (2019) (22)
- Prolonged Recurrent Abdominal Pain is Associated With Ongoing Underlying Mucosal Inflammation in Patients who had an Episode of Acute Complicated Diverticulitis (2019) (21)
- Automated detection of Crohn's disease intestinal strictures on capsule endoscopy images using deep neural networks. (2020) (21)
- Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time? (2015) (21)
- Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure (2015) (20)
- Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy. (2018) (20)
- Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial. (2019) (20)
- Functional Voltage-Gated Sodium Channels Are Expressed in Human Intestinal Epithelial Cells (2008) (19)
- Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: A multicenter Israeli study (2020) (19)
- Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases (2018) (19)
- Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease (2017) (19)
- alpha1beta1 Integrin+ and regulatory Foxp3+ T cells constitute two functionally distinct human CD4+ T cell subsets oppositely modulated by TNFalpha blockade. (2007) (19)
- Main Imaging Features of Crohn's Disease: Agreement between MR-Enterography and CT-Enterography. (2015) (18)
- Expression of the alpha1beta1 integrin, VLA-1, marks a distinct subset of human CD4+ memory T cells. (2003) (18)
- The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors (2017) (18)
- Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment with TNFα Antagonists (2019) (17)
- Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. (2021) (16)
- Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays (2016) (16)
- Over-reaching beyond disease activity: the influence of anxiety and medical economic burden on health-related quality of life in patients with inflammatory bowel disease (2016) (16)
- Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-drug Antibodies. (2019) (16)
- Thiopurine Effectiveness in Patients with Crohn's Disease: A Study of Genetic and Clinical Predictive Factors (2013) (16)
- Different clinical outcomes in Crohn’s disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype? (2018) (15)
- Structural bowel damage in quiescent Crohn's disease. (2017) (15)
- Systematic review with meta‐analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations (2021) (15)
- Re-phrasing the question: A simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease (2017) (15)
- Synovial VLA-1+ T cells display an oligoclonal and partly distinct repertoire in rheumatoid and psoriatic arthritis. (2008) (14)
- Epidemiology of Inflammatory Bowel Diseases in Israel: A Nationwide Epi-Israeli IBD Research Nucleus Study. (2021) (14)
- Brunner's gland hamartoma presenting as a large duodenal polyp. (2000) (14)
- Thalidomide induces clinical remission and mucosal healing in adults with active Crohn’s disease: a prospective open-label study (2017) (14)
- Treatment of experimental colitis through induction of oral tolerance towards colitis-extracted proteins (1998) (13)
- Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease (2016) (13)
- Flare-up of ulcerative colitis after systemic corticosteroids: a strong case for Strongyloides. (2008) (13)
- Clinical and radiographic presentation of superior mesenteric vein thrombosis in Crohn's disease: a single center experience. (2012) (13)
- Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis (2019) (13)
- Significance of low level infliximab in the absence of anti-infliximab antibodies. (2015) (13)
- Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease. (2021) (13)
- Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay (2016) (13)
- DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease (2019) (12)
- Intracavitary Contrast-enhanced Ultrasonography to Detect Enterovesical Fistula in Crohn's Disease. (2016) (12)
- Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn’s disease (2017) (12)
- 11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial (2013) (12)
- Impact of COVID‐19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China (2020) (12)
- Surgical management of inflammatory bowel disease in China: a systematic review of two decades (2016) (12)
- Monitoring of small bowel Crohn’s disease (2017) (12)
- Tu1158 Evaluating Adalimumab Drug and Antibody Levels As Predictors of Clinical and Laboratory Response in Crohn's Disease Patients (2013) (12)
- Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. (2019) (11)
- The accuracy of intestinal ultrasound compared with small bowel capsule endoscopy in assessment of suspected Crohn’s disease in patients with negative ileocolonoscopy (2018) (11)
- Diffusion-weighted magnetic resonance enterography for prediction of response to tumor necrosis factor inhibitors in stricturing Crohn’s disease (2018) (11)
- Pseudomembranes in a patient with flare-up of inflammatory bowel disease (IBD): is it only Clostridium difficile or is it still an IBD exacerbation? (2010) (11)
- Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study (2019) (11)
- Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice (2017) (10)
- A patient with ulcerative colitis and central serous chorioretinopathy--a therapeutic dilemma. (2013) (10)
- Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease. (2020) (10)
- Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn’s Disease (2020) (10)
- 6-Thioguanine Nucleotide Levels Are Associated With Mucosal Healing in Patients With Crohn's Disease. (2018) (10)
- Capsule Endoscopy Validation of the Magnetic Enterography Global Score in Patients with Established Crohn’s Disease (2018) (10)
- Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms. (2021) (10)
- The risk of advanced histology in small-sized colonic polyps: are non-invasive colonic imaging modalities good enough? (2012) (10)
- Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease (2019) (10)
- The impact of pseudomembrane formation on the outcome of Clostridium difficile-associated disease (2013) (10)
- Rarity of adenomatous polyps in ulcerative colitis and its implications for colonic carcinogenesis (2015) (10)
- Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease (2018) (9)
- Intra-Cavitary Contrast-Enhanced Ultrasound: A Novel Radiation-Free Method for Detecting Abscess-Associated Penetrating Disease in Crohn’s Disease (2018) (9)
- Factors associated with the achievement of mucosal healing in Crohn’s disease: the benefit of endoscopic monitoring in treating to target (2017) (9)
- Inflammatory Bowel Disease: An Emergent Disease Among Ethiopian Jews Migrating to Israel (2015) (9)
- World Congress Integrative Medicine & Health 2017: part two (2017) (9)
- Rising prevalence of celiac disease is not universal and repeated testing is needed for population screening (2019) (9)
- Celiac Disease Resolution After Allogeneic Bone Marrow Transplantation is Associated with Absence of Gliadin-Specific Memory Response by Donor-Derived Intestinal T-cells (2013) (9)
- Gastroenteritis-associated hyperamylasemia: prevalence and clinical significance. (2002) (9)
- Familial ulcerative colitis in Israeli Jews: its prevalence and clinical severity compared to sporadic disease (2011) (8)
- Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents. (2015) (8)
- Sa1150 Early Initiation of Adalimumab Significantly Diminishes Post-Operative Crohn's Disease Recurrence, and Is Superior to Immunomodulator Therapy. Preliminary Results From the POPART Trial (2015) (8)
- Tu2018 - Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease (2018) (8)
- Partners of patients with inflammatory bowel disease: how important is their support? (2014) (8)
- Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor (2018) (8)
- OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis (2020) (8)
- Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients is Not Rare and Possibly Predictable. (2020) (7)
- Infliximab therapy intensification upon loss of response: Is there an optimal trough level? (2019) (7)
- Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis (2011) (7)
- Artificial Intelligence-Aided Colonoscopy Does Not Increase Adenoma Detection Rate in Routine Clinical Practice (2022) (7)
- Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease (2020) (6)
- Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease (2020) (6)
- Low 6‐thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease (2018) (6)
- Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. (2020) (6)
- P517 Evaluating Adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients (2013) (6)
- Assessment of patency capsule retention using MR diffusion-weighted imaging (2017) (6)
- Head or Tail: The Orientation of the Small Bowel Capsule Endoscope Movement in the Small Bowel (2012) (6)
- Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies (2018) (6)
- Discontinuation of Biological Treatments in Inflammatory Bowel Disease: A Concise Pragmatic Review (2017) (6)
- Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease (2017) (6)
- CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease (2019) (6)
- Risk of metachronous neoplasia on surveillance colonoscopy among young and older patients after polypectomy. (2020) (5)
- Evolution of Inflammatory Bowel Disease Research From a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics. (2020) (5)
- European experience with methotrexate treatment in Crohn’s disease: a multicenter retrospective analysis (2016) (5)
- The Effect of Blockade of Tumor Necrosis Factor α on VLA-1+T-Cells in Rheumatoid Arthritis Patients (2007) (5)
- Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases (2022) (5)
- Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (2022) (5)
- Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort (2020) (5)
- Localized pericardial inflammation in systemic lupus erythematosus. (2004) (5)
- Superficial abdominal thrombophlebitis (Mondor's disease) presenting as loss of response to adalimumab in a Crohn's disease patient. (2014) (5)
- Barriers to international travel in inflammatory bowel disease patients. (2020) (5)
- P122 The clinical and immunological significance of low level of infliximab in the absence of anti-infliximab antibodies in patients with IBD (2014) (5)
- Thromboprophylaxis for Hospitalized Patients with Inflammatory Bowel Disease—Are We There Yet? (2020) (4)
- DOP074 Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: A meta-analysis (2014) (4)
- 948 A NOVEL SUBCUTANEOUS INFLIXIMAB (CT-P13) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: WEEK54 AND SWITCHING RESULTS FROM A MULTICENTER, RANDOMISED CONTROLLED PIVOTAL TRIAL (2020) (4)
- P545 Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition (2018) (4)
- UEG Week 2016 Poster Presentations (2016) (4)
- Tu1167 Infliximab Is More Immunogenic and Reaches Lower Trough Levels in Ulcerative Colitis Patients Compared to Crohn's Disease Patients (2013) (4)
- Vedolizumab Induction Therapy for Patients With Crohn’s Disease and Prior Anti‐TNF Antagonist Failure: A Randomized, Placebo‐controlled, Double‐blind, Multicenter Trial: P‐26 (2012) (4)
- Detection of Ustekinumab in Breast Milk of Nursing Mothers With Crohn Disease. (2021) (4)
- Combination of Corticosteroids with 5-Aminosalicylic Acids Compared to Corticosteroids Alone for Hospitalized Patients with Active Ulcerative Colitis. (2016) (4)
- Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study (2022) (4)
- Infliximab levels and antibodies in IBD-related peripheral arthralgia (2020) (4)
- Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial (2023) (4)
- Curcumin Add-on Therapy for Remission Induction in Mild-moderate Active Ulcerative Colitis: A Multi-center, Randomized, Placebo-Controlled Trial (2015) (4)
- Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors’ reply (2017) (3)
- Correction to: Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5+ B regulatory cells (2019) (3)
- Integrin and Regulatory Foxp3 T Cells Constitute Two Functionally Distinct Human CD4 T Cell Subsets Oppositely Modulated by TNF Blockade (2006) (3)
- A Convolutional Neural Network Deep Learning Model Trained on CD Ulcers Images Accurately Identifies NSAID Ulcers (2021) (3)
- Change in bowel habits during menstruation: are IBD patients different? (2020) (3)
- UEG Week 2016 Oral Presentations (2016) (3)
- Implications of COVID-19 for patients with pre-existing digestive diseases: an update (2021) (3)
- P392 Comprehensive video capsule endoscopy-based monitoring predicts short and long-term risk of disease flares in small bowel Crohn’s disease: A prospective cohort study (2018) (3)
- Biologics' switching: new insights toward establishing practice norms (2019) (3)
- The Effect of Blockade of Tumor Necrosis Factor α on VLA-1+T-Cells in Rheumatoid Arthritis Patients (2007) (3)
- Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials (2019) (3)
- Evolution of colorectal cancer screening research in the past 25 years: text-mining analysis of publication trends and topics (2020) (3)
- A giant left ventricular pseudoaneurysm as a late sequela of aortic valve endocarditis. (2003) (3)
- DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study (2018) (2)
- P571 Effectiveness and safety of Ustekinumab for induction of remission in patients with Crohn's disease: a multi-centre Israeli study (2019) (2)
- P177 Lower vedolizumab trough levels before interval shortening are not predictive of success of the intervention (2020) (2)
- S0652 Real World Exposure-Response Relationship of Vedolizumab in Inflammatory Bowel Disease: A Pooled Multicenter Observational Cohort Analysis of Clinical and Modeled Pharmacological Data (2020) (2)
- Tu1715 – A Novel Formulation of Ct-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 1-Year Result from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease (2019) (2)
- The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD) (2022) (2)
- Su1121 Anti-TNF and Anti-Drug Antibodies Levels Predict the Outcomes of Interventions After Loss of Response to Adalimumab and Infliximab (2014) (2)
- Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study (2021) (2)
- Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα (2021) (2)
- Sa1174 The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Classification of Disease in Patients With Known Crohn's Disease: A Prospective Israeli IBD Research Network (IIRN) Study (2015) (2)
- P679 Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects (2019) (2)
- Sa1953 Addition of an Immunomodulator Can Reverse Antibody Formation and Loss of Response in Patients Treated With Adalimumab (2016) (2)
- Postoperative outcomes following inguinal hernia repair in inflammatory bowel disease patients compared to matched controls. (2020) (1)
- A nerve-racking syncope. (2002) (1)
- Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases. (2020) (1)
- Berberine Alone and in Conjunction With Immunomodulators Down-regulates Pro-inflammatory CD4+ T-Cells: Implications for a Combined Treatment of Inflammatory Bowel Diseases (2015) (1)
- Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma (2022) (1)
- Sa 1233 Anti- TNFs and Post-Operative Complications in Crohn's Disease: Systematic Review and Meta-Analysis (2012) (1)
- Letter: loss of response to anti‐TNFα agents in patients with inflammatory bowel disease depends on treatment duration (2022) (1)
- Therapeutic drug monitoring in infl ammatory bowel disease (2014) (1)
- DOP062 Predictors of formation of antibodies to infliximab (ATI) and secondary loss of response in IBD patients treated with infliximab (2014) (1)
- P775 Evolution of inflammatory bowel disease research from a bird’s eye perspective: A text-mining analysis of publication trends and topics (2020) (1)
- AODWE-008 Multicentre ecco collaborative group study to evaluate the need for re-intervention following multimodal treatment in crohn`s disease with perianal fistula (2017) (1)
- P181 Home smart-phone based measurement of fecal calprotectin by IBD patients: correlation with laboratory assay and applicability as patient-friendly monitoring tool. (2017) (1)
- Editorial: biomarker predictors of non‐response to TNFα antagonists—the quest continues (2019) (1)
- P160 Pan-enteric mucosal inflammation in CD patients treated with vedolizumab – interim results of a prospective observational study using a panenteric capsule (PiilCam CD) (2022) (1)
- Keeping it simple: mental health assessment in the Gastroenterology Department – using the Hospital Anxiety and Depression Scale (HADS) for IBD patients in Israel (2022) (1)
- The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018 (2022) (1)
- P313 Within, 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses (2022) (1)
- Prediction of Recurrent Emergency Department Visits among Patients with Crohn’s Disease: A Retrospective Study (2020) (1)
- Body, Soul, and Hypnotherapy. (2021) (1)
- P01-033 – Co-occurance of Crohn’s disease and FMF (2013) (1)
- Tu1278 Infliximab and Adalimumab Serum Levels Predict Probability of Mucosal Healing (2015) (1)
- CURCUMIN-QINGDAI COMBINATION FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED CLINICAL TRIAL (2023) (1)
- Reversal of Immunogenicity in Inflammatory Bowel Disease. (2017) (1)
- DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study (2020) (1)
- P402 Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's disease: outcomes and risk factors associated with relapse. (2017) (1)
- P406 A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries (2021) (1)
- Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study. (2022) (1)
- Corticosteroids and 5-ASA versus corticosteroids for acute severe ulcerative colitis: A randomized controlled trial. (2022) (1)
- Su1178 - Serum MMP-9 - A Novel Biomarker for Prediction of Clinical Relapse in Patients with Quiescent small Bowel Crohn's Disease (2018) (1)
- W1322 The Practice of North-American Gastroenterologists in Treating IBD Patients With C.Difficile: Antibiotics Alone or Combined Antibiotics-Immunomodulators? (2010) (1)
- Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (2022) (1)
- Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. (2017) (1)
- P785 The prevalence of inflammatory bowel disease doubled in the last decade in Israel: an epiIIRN national population-based study (2019) (1)
- QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE (2023) (1)
- 19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study (2016) (1)
- Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD (2022) (1)
- Predictors of mortality in inflammatory bowel disease patients treated for pneumonia (2020) (1)
- Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus Erythematosus. (2016) (1)
- Thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection: Strategy based on risk stratification (2018) (1)
- Acute Chest Pain as an Infusion Reaction to Vedolizumab (2022) (1)
- 143 PEG-Based Bowel Preparation Does Not Impact Small Bowel (SB) Cleansing Level or Diagnostic Yield in Real Life Video Capsule Endoscopy (VCE) Procedures -A Two Center Comparative Experience (2014) (1)
- Machine learning for prediction of intra-abdominal abscesses in patients with Crohn’s disease visiting the emergency department (2021) (1)
- Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis (2022) (1)
- Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES (2022) (1)
- Qualitative sonographic assessment of transmural ileal inflammation in Crohn's disease: a comparison with MRI activity score. (2020) (1)
- 44 – Infliximab Clearance is Decreased During 2Nd and 3Rd Trimesters of Pregnancy in Inflammatory Bowel Disease (2019) (1)
- P366 The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with inflammatory bowel disease - a multicenter European real world experience. (2017) (1)
- P428 Optimizing thiopurines in Crohn's disease: low dose and low 6-TGN level are effective for maintenance of remission in Asian population. (2017) (1)
- Patency capsule: A novel independent predictor for long-term outcomes among patients with quiescent Crohn's disease. (2022) (1)
- Sa1106 Adalimumab Monotherapy Versus Combination Therapy With Adalimumab and Immunomodulators for Crohn's Disease: A Meta-Analysis (2014) (1)
- Letter: double‐dose intensification—a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply (2019) (1)
- P014 Untargeted serum metabolome in longitudinal Crohn’s Disease (CD) cohort enrolled during remission shows strong individualized signature and CD-associated signals that are maintained also in patients who normalized their fecal calprotectin (2021) (0)
- Bottom-up: Can Trans-anal Rectal Resection Improve Outcomes in Ulcerative Colitis Patients Undergoing Proctocolectomy and Ileo-anal Pouch Anastomosis? (2020) (0)
- Cytomegalovirus Limited to the Rectum in an Immunosuppressed IBD Patient. (2021) (0)
- P012 α4β7 Receptor occupancy by vedolizumab at trough time-point occurs at the membranal level and is not associated with endoscopic healing in inflammatory bowel disease patients (2020) (0)
- Editorial: restoring therapeutic infliximab drug levels in patients with loss of response—pharmacokinetics and anti‐drug antibodies as useful guidance tools (2018) (0)
- P350 Endoscopic sedation in IBD patients: a propensity score-matched retrospective study (2023) (0)
- Su1809 Combining Anti-Inflammatory Treatment With Antiviral Treatment in Severe CMV Positive Ulcerative Colitis Does Not Affect Colectomy Rate: A Retrospective Multicenter Study (2016) (0)
- P240 Presentation and surgical interventions for Crohn's disease with perianal fistula in the biologics era: results from a multicentre study. (2017) (0)
- P635 Risankizumab - real world Israeli data in severe refractory IBD patients (2023) (0)
- Urine Dripping From the Sigmoid Wall in a Patient With Suspected Crohn's Disease: An Unusual Manifestation of a Colonovesical Fistula (2017) (0)
- DOP60 Self-reported treatment effectiveness for Crohn’s Disease using a novel crowdsourcing web-based platform (2022) (0)
- Novel therapies for ulcerative colitis (2013) (0)
- Detectionofinfliximabinbreastmilkofnursingmothers with inflammatory bowel disease (2011) (0)
- P785 Predictors of mortality in IBD patients treated for pneumonia (2020) (0)
- P441 Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. (2017) (0)
- Design How / When Concomitant IMMs [ n ( % ) ] Fecal Calprotectin ( μ g / g ) Blood In fl ammatory Markers Clinical Studies Predictors (2017) (0)
- Authors' response (2011) (0)
- Response to Hassan et al. (2022) (0)
- P129 - The impact of concomitant treatment with immuno-modulators and antibiotics on the outcome of C. difficile -associated inflammatory bowel disease exacerbation: an ECCO multi-center retrospective study (2009) (0)
- Su2051 – Intracolic Molecular Ultrasound Imaging for Non-Invasive and Quantitative Assessment of Tumor Necrosis Factor-α Expression in Inflammatory Bowel Disease (2019) (0)
- Adverse Clinical Outcomes among Inflammatory Bowel Disease Patients Treated for Urinary Tract Infection (2022) (0)
- P312 Combination corticosteroids with, 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: A multi-center randomized controlled trial (2022) (0)
- Distal fecal wash host transcriptomics identifies inflammation throughout the colon and terminal ileum. (2023) (0)
- P409 Immunity to varicella zoster in IBD patients treated with TNF inhibitors (2012) (0)
- Iconographies supplémentaires de l'article : Prediction of patency capsule retention in known Crohn's disease patients by using magnetic resonance imaging (2016) (0)
- P341 Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice. (2017) (0)
- P779 CD patients in deep remission harbor a high dysbiosis index similar to active CD at diagnosis, yet both are higher in comparison to healthy controls. (2017) (0)
- P332 Multinational comparisons of practices in overseas travel in Crohn’s disease and ulcerative colitis (2019) (0)
- Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe? (2021) (0)
- P640 Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel Diseases (2023) (0)
- COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience (2022) (0)
- [Fever and chills following intravenous administration of NeyTumorin--an unconventional xenogenous derived peptides extract]. (2002) (0)
- P755 Safety, efficacy, and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-TNF (2018) (0)
- P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience (2021) (0)
- P806 Perianal Crohn’s Disease (pCD): The outcome of 2nd line and 3rd line biologics in perianal Crohn’s disease (2023) (0)
- Mo1261 Thrombosis in Inflammatory Bowel Disease Patients Is Driven by Inflammation Rather Than by Thrombophilia (2014) (0)
- P173 Patency capsule: A novel independent predictor for long-term outcomes among patients with quiescent Crohn’s disease (2023) (0)
- P056 Exposures linked with urban and rural living indicate that living in rural area but spending above 50% of daily-life in urban environment is linked with reduction in alpha-diversity, reduced rural index, and reduced microbial health index mirroring CD profile (2023) (0)
- Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply (2018) (0)
- P643 Development of quantitative ultrasonographic activity score in ileal Crohn’s disease (2020) (0)
- P269 Spaciotemporal machine learning analysis of complete small bowel capsule endoscopy videos for prediction of outcomes in Crohn’s disease (2022) (0)
- GATA6-AS1 regulates intestinal epithelial mitochondrial functions, and its reduced expression is linked to intestinal inflammation and less favorable disease course in ulcerative colitis (UC). (2023) (0)
- P189 Diffusion-weighted magnetic resonance enterography for prediction of response to tumour necrosis factor inhibitors in stricturing Crohn’s disease (2018) (0)
- Visible worms in a Crohn's patient treated with Infliximab. (2020) (0)
- P043 The effects of IBD biologic drugs on the propagation of lymphomatous transformation of EBV-infected peripheral blood mononuclear cells (2018) (0)
- Tu1324 Unfavorable Initial Thiopurine Response Does Not Reduce Anti-Drug Antibody Formation Compared to Thiopurine Responders in Crohn's Disease Patients Treated by Thiopurine & Infliximab Co-Therapy (2015) (0)
- P305 Intra-cavitary contrast-enhanced ultrasound: A novel radiation-free method to detect abscess associated internal fistulas in Crohn’s disease (2018) (0)
- P190 Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with Quiescent Small Bowel Crohn’s disease (2018) (0)
- P718 Combination therapy of adalimumab with an immunomodulator is not more effective than adalimumab monotherapy in children with Crohn’s disease (2020) (0)
- [Inflammatory bowel disease--infectious, environmental, genetic and immune mechanisms of pathogenesis]. (2000) (0)
- Explorer Second European evidence-based consensus on the prevention , diagnosis and management of opportunistic infections in inflammatory bowel disease (2017) (0)
- Mo1382 Inflammatory Bowel Disease Characteristics Among Ethiopian Jews: A Multicenter Study (2013) (0)
- Tu1954 Capsule Endoscopy Findings and Fecal Calprotectin Levels Predict Clinical Relapse in Patients With Quiescent Small Bowel Crohn's Disease (2016) (0)
- P473 Infliximab is more immunogenic and reaches lower trough levels in ulcerative colitis patients compared to Crohn's disease patients (2013) (0)
- P016 Recurrent Prolonged Antigen Encounters are Necessary For 6-MP Induced Clonal Deletion of Antigen-Specific Memory T-Cells in Vivo (2007) (0)
- P512 Elimination of detectable anti-infliximab antibodies and reversal of loss of response by the addition of an immuno-modulator (2013) (0)
- W1091 The Impact of Concomitant Treatment with Immuno-Modulators and Antibiotics On the Outcome of C. difficile-Associated Inflammatory Bowel Disease Exacerbation: A European Multi-Center Retrospective Study (2009) (0)
- DEVELOPMENT AND VALIDATION OF A MACHINE LEARNING TOOL FOR EARLY DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE IN THE PRIMARY CARE SETTING: A POPULATION BASED STUDY (2022) (0)
- Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial (2023) (0)
- Risk factors and prediction algorithm for advanced neoplasia on screening colonoscopy for average-risk individuals (2022) (0)
- Corrigendum (2020) (0)
- P479 The effect of adalimumab on linear growth in children with Crohn’s disease: a post hoc analysis of the PAILOT randomised control trial (2020) (0)
- P211 Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 multicentre fistula cohorts. (2017) (0)
- DOP089 Individualised variations in the gut microbiota during remission precede Crohn’s disease flares (2018) (0)
- Sa1867 LOWER VEDOLIZUMAB TROUGH LEVELS BEFORE INTERVAL SHORTENING ARE NOT PREDICTIVE OF SUCCESS OF THE INTERVENTION (2020) (0)
- P221 Thromboembolic events in hospitalised patients with inflammatory bowel disease – a large tertiary hospital experience (2020) (0)
- DOP30 Identifying dietary factors and metabolites that may promote healthier Crohn Disease microbiome and mucosal transcriptomics signals as future targets using Diet-Omics (2023) (0)
- P676 Intestinal ultrasound accurately predicts therapy failure in Crohn's disease patients during a biologics-induced remission (2023) (0)
- P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease? (2022) (0)
- 117 Diagnostic Yield of Capsule Endoscopy Versus Magnetic Resonance Enterography and Small Bowel Contrast Ultrasound for Evaluation of Small Bowel Crohn's Disease; a Systematic Review and Meta-Analysis (2017) (0)
- Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment - The Authors' reply (2011) (0)
- INCIDENTALLY DIAGNOSED ASYMPTOMATIC CROHN’S DISEASE: LONG-TERM CLINICAL OUTCOMES OF UNTREATED PATIENTS (2022) (0)
- Su1224 Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease (2015) (0)
- DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case–control study (2020) (0)
- P032 Host transcriptome signatures in human fecal-washes predict histological remission in IBD patients (2022) (0)
- Mo1580 Prediction of Patency Capsule Retention by MR Enterography in Patients With Known Crohn's Disease: (2015) (0)
- P481 Serum levels of infliximab associate with early mucosal healing in Crohn's disease: different "therapeutic window" between post-induction and maintenance treatment. (2017) (0)
- P721 A switch in the prevalence ratio of Crohn's disease vs. ulcerative colitis in Israel between 2003 and 2015 - a report from the epi-IIRN group. (2017) (0)
- 239 THE EARLY APPEARANCE OF ANTI-DRUG ANTIBODIES DURING THE INDUCTION PHASE PREDICTS THE CLINICAL RESPONSE OF ADALIMUMAB AND INFLIXIMAB IN IBD (2020) (0)
- P344 What our patients are looking for - the common fields of interest in IBD patients: A Google Trends Analysis (2022) (0)
- Wholistic approach to IBD patients. (2021) (0)
- Detectionof infliximab in breastmilk of nursingmothers with inflammatory bowel disease (2011) (0)
- Cl in ical Problem-Solv ing A Nerve-Racking Syncope (2002) (0)
- P494 Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula. (2017) (0)
- OC-072 Differences in therapy approaches and outcomes in paediatric and adult onset crohn’s disease with perianal fistula: comparison of 2 ecco collaborative multicentre fistula cohorts (2017) (0)
- W1912 Efficacy of Shortening the Dosing Interval to Once in Six Weeks in Crohn's Disease Patients That Failed the Standard Maintenance Dose of Infliximab (2010) (0)
- PWE-033 Presentation and surgical interventions for crohn’s diseasewith perianal fistula in the biologics era: results from a multicentre study (2017) (0)
- Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study (2023) (0)
- Multicentre Cohort Study to Evaluate the Need for Re-Intervention following Multimodal Treatment in Crohn`s Disease with Perianal Fistula (2017) (0)
- CORTICOSTEROIDS AND 5ASA VERSUS CORTICOSTEROIDS ALONE FOR ACUTE SEVERE ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL (2022) (0)
- P400 Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection. (2017) (0)
- P623 The effectiveness and tolerability of Crohn’s disease exclusion diet in adult Crohn’s disease patients: a retrospective study (2022) (0)
- PTU-072 Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study (2016) (0)
- P188 Middle small-bowel segment Lewis score may predict long-term outcomes among patients with quiescent Crohn’s disease (2023) (0)
- OP31 Dietary and Multi-Omic characterization of new onset treatment naive Crohn Disease identifies factors that may contribute to disease pathogenesis (2022) (0)
- 324 Quantification of Inflammation in Small Bowel Crohn's Disease Patients by Videocapsule Endoscopy and Magnetic Resonance Enterography (2015) (0)
- 1135: STUDY OF URBAN AND RURAL CROHN DISEASE EVOLUTION (SOURCE) INDICATES THAT DIET, EXPOSURE TO URBAN LIFESTYLE, AND CROHN DISEASE ARE SIGNIFICANT DETERMINANTS OF THE HUMAN GUT MICROBIOME IN CHINA AND ISRAEL (2022) (0)
- P246 Risk factors associated with low ovarian reserve in young women of reproductive age with Crohn's disease. (2017) (0)
- P560 Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial (2023) (0)
- Sa1966 Early Infliximab Drug Levels Predict Perianal Fistula Response to Treatment (2016) (0)
- Editorial: which biologic is next for ulcerative colitis patients who fail a subcutaneous anti‐TNF? (2020) (0)
- P109 Using baseline Peripheral blood mononuclear cell (PBMC) transcriptomics of Crohn Disease patients receiving Ustekinumab treatment as a tool to assess potential response at 1 year (2023) (0)
- P160 A novel PillCam Crohn’s capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn’s disease (2020) (0)
- Abstracts from the Fourteenth Rambam Research Day, December 7, 2017 (2018) (0)
- Tu1419 Ingestion of Inert Colonic Markers As a Novel Method for Predicting the Quality of Preparation for Colonoscopy (2011) (0)
- P372 Severe obesity in Crohn's disease patients: prevalence and disease associations (2013) (0)
- Tu1298 Anti-Infliximab Antibodies With Neutralizing Capacity in Inflammatory Bowel Disease Patients: Distinct Clinical Implications Revealed by a Novel Assay (2015) (0)
- 347 - Impact of Drug Levels, Anti-Drug Antibodies and α4β7 Target Occupnacy on the Response to Vedolizumab Therapy in Patients with Inflmmatory Bowel Disease (2018) (0)
- N820 The value and perception of IBD patients on electronic news letter as a mode of patient-medical team communication. (2017) (0)
- P450 Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease (2022) (0)
- P449 Inflammatory bowel disease patients' partner – how important is their support? (2014) (0)
- Tu1877 EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC RESULT IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFILXIMAB SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL (2020) (0)
- Disproportionately Low Albumin and High Neutrophil-to-Lymphocyte Ratio in Small Bowel Adenocarcinoma Patients With Long-Duration Crohn's Disease (2022) (0)
- P421 Correlation of bowel activity parameters in intestinal ultrasound to drug retention and trough drug levels in Crohn’s disease (2022) (0)
- P524 Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study (2023) (0)
- P515 Inflammatory bowel disease and malignancy – the outcome of patients with malignancy diagnosed before IBD diagnosis or IBD-targeted therapy (2022) (0)
- P381 Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis (2022) (0)
- Incidentally Diagnosed Asymptomatic Crohn’s Disease: A Retrospective Cohort Study of Long-Term Clinical Outcomes (2022) (0)
- 599 - Comprhensive Video Capsule Endosocpy-Based Monitoring Predicts Short and Long-Term Risk of Disease Flares in Small Bowel Crohn's Disease: A Prospective Cohort Study (2018) (0)
- Letter: persistence of anti‐infliximab antibodies after discontinuation of infliximab in patients with IBD – authors’ reply (2012) (0)
- Hardly Ants-ipated capsule endoscopy finding. (2022) (0)
- Ultrasound-Tomographic Image Fusion: A Novel Imaging Technique for Follow-Up of Penetrating Complications of Crohn's Disease. (2022) (0)
- P302 - Innate immune suppression by trace metals – an unexpected role in the pathogenesis of Crohn's disease? (2009) (0)
- Presentation and Surgical Interventions for Crohn's Disease with Perianal Fistula in the Biologics Era: Results from a Multicentre Study (2017) (0)
- Sa1708 - The Effect of IBD Biologic Drugs on Lymphomatous Transformation of EBV-Infected Peripheral Blood Mononuclear Cells (2018) (0)
- DOP36 Gut microbial variations in patients with quiescent Crohn’s disease predict subsequent disease flare (2019) (0)
- P676 Burden of depression and anxiety among inflammatory bowel disease patients in a national cohort in Israel – Data from the EPI-IIRN (2022) (0)
- Sa1175 Clinical Outcomes of Surgery Versus Endoscopic Balloon Dilatation for Stricturing Crohn's Disease (2015) (0)
- Mo1887 - Safety, Efficacy and Pharmacokinetics of Vedolizumab in Patients with Simultaneous Exposure to an Anti-TNF (2018) (0)
- P402 Prediction of emergency department re-visit among Crohn’s disease patients: a retrospective study (2020) (0)
- P624 Chromoendoscopy and narrow band imaging versus conventional white light endoscopy for detection of neoplasia in ulcerative colitis - a systematic review and meta-analysis. (2017) (0)
- Deep Learning Multi-Domain Model Provides Accurate Detection and Grading of Mucosal Ulcers in Different Capsule Endoscopy Types (2022) (0)
- Signs and Symptoms of Acute Bowel Inflammation and the Risk of Progression to Inflammatory Bowel Disease: A Retrospective Analysis (2022) (0)
- P565 Infliximab therapy intensification upon loss of response: what should be the cut-off for trough levels? (2019) (0)
- A Meta-Analysis of Environmental and Dietary Risk Factors for Inflammatory Bowel Disease: A Comparison Between Eastern and Western Populations (2021) (0)
- P572 Coexisting Inflammatory bowel disease and Ankylosing spondylitis: Management and clinical outcomes (2023) (0)
- Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients. (2021) (0)
- Automatized Detection of Crohn's Disease in Intestinal Ultrasound Using Convolutional Neural Network. (2023) (0)
- Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5+ B regulatory cells (2016) (0)
- FRI0207 The input of measuring of infliximab and adalimumab levels and levels of antibodies to these drugs in the management of patients with autoimmune diseases treated with anti tnf monoclonal antibodies. (2013) (0)
- N13 Low compliance with remote monitoring of patient-reported outcomes via digital application in patients with inflammatory bowel disease (2023) (0)
- Mo1907 - 6-Thioguanine Nucleotide Levels are Associated with Mucosal Healing in Patients with Crohn's Disease: A Multicenter International Study (2018) (0)
- N05 Patient involvement in Inflammatory Bowel Disease therapy and disease-related parameters - Is there an association? (2022) (0)
- Mo1066 Chromoendoscopy and Narrow Band Imaging Versus Conventional White Light Endoscopy for Detection of Neoplasia in Ulcerativ E.ColiTis- a Systematic Review and Meta-Analysis (2017) (0)
- Assays used to assess biosimilarity of therapies for inflammatory bowel disease (2019) (0)
- Sa1783 - Intra-Cavitary Contrast-Enhanced Ultrasound: A Novel Radiation-Free Method to Detect Abscess Associated Internal Fistulas in Crohn's Disease (2018) (0)
- P048 Bridging the Gap Between Body and Soul: A Pilot Study Examining Inflammation and Depression / Anxiety in Inflammatory Bowel Disease Patients (2022) (0)
- P160 Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound for evaluation of small bowel Crohn's disease: a systematic review and meta-analysis. (2017) (0)
- SPACIOTMEPORAL MACHINE LEARNING ANALYSIS OF COMPLETE SMALL BOWEL ENDOSCOPY VIDEOS FOR PREDICTION OF OUTCOMES IN CROHN'S DISEASE (2022) (0)
- 1150 – Intra-Personal Gut Microbial Variations in Patients with Quiescent Crohn Disease Predict Subsequent Disease Flare (2019) (0)
- Correction to: Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5+ B regulatory cells (2019) (0)
- The Traveling IBD Patient – A Case-Controlled Study of Travel-Associated Health Risks (2011) (0)
- P122 Machine learning for prediction of intra-abdominal abscesses in patients with Crohn’s disease visiting the emergency department (2021) (0)
- A New Diagnosis Standard for Enterovesical Fistula in Crohn's Disease by Intracavitary Contrast-Enhanced Ultrasound (2017) (0)
- To appear in : Digestive and Liver Disease (2017) (0)
- Sa1735 – Baseline Bowel Stiffness on Real-Time Shear Wave Ultrasound Elastography Predicts Response to Infliximab in Patients with Crohn's Disease (2019) (0)
- P046 Crohn Disease (CD) untargeted fecal metabolome shows strong correlation with specific salivary associated microbial taxa, and with disease activity (2023) (0)
- P209 Disproportionate low albumin and high neutrophil-to-lymphocyte ratio in small bowel adenocarcinoma in long-term Crohn’s disease patients (2022) (0)
- P245 Clinical and radiographic presentation of superior mesenteric vein thrombosis in Crohn's disease (2012) (0)
- 794: DIETARY AND MULTI-OMICS CHARACTERIZATION OF NEW ONSET TREATMENT NAIVE CROHN DISEASE IDENTIFIES FACTORS THAT MAY CONTRIBUTE TO DISEASE PATHOGENESIS (2022) (0)
- P551 6-Thioguanine nucleotide levels are associated with mucosal healing in patients with Crohn’s disease: A multi-centre, international study (2018) (0)
- Immune function in newborns with in-utero exposure to anti-TNFα therapy (2022) (0)
- P486 Response to vedolizumab therapy in patients with inflammatory bowel disease: Impact of drug levels, anti-drug antibodies and α4β7 target occupancy (2018) (0)
- P267 Real-world artificial intelligence-aided colonoscopy does not improve adenoma detection rates in patients with Inflammatory Bowel Disease (2023) (0)
- Celiac Disease Resolution After Allogeneic Bone Marrow Transplantation is Associated with Absence of Gliadin-Specific Memory Response by Donor-Derived Intestinal T-cells (2013) (0)
- DOP62 Efficacy of biologic drugs in short-duration versus long-duration Inflammatory Bowel Disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials (2022) (0)
- P724 Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels (2020) (0)
- P004 Untargeted serum metabolome shows Crohn Disease (CD) associated signature, signals that correlate with disease activity and CRP, and signals that may precede disease flare (2023) (0)
- Sa1399 Soluble Syndecan-1: A Potential Novel Biomarker of Small Bowel Mucosal Damage in Children With Celiac Disease (2016) (0)
- Fr511 IMMUNE FUNCTION IN NEWBORNS OF FEMALES WITH GESTATIONAL ANTI- TNFα MEDICATION THERAPY FOR INFLAMMATORY BOWEL DISEASE (2021) (0)
- Editorial: tofacitinib post‐marketing safety reports among ulcerative colitis patients (2021) (0)
- P192 First event of acute intestinal inflammation and the risk of progression to Inflammatory bowel disease: a retrospective analysis (2022) (0)
This paper list is powered by the following services:
Other Resources About Shomron Ben-Horin
What Schools Are Affiliated With Shomron Ben-Horin?
Shomron Ben-Horin is affiliated with the following schools:
